Informations générales (source: ClinicalTrials.gov)
Detection of Spinal Cord Lesions Using the MP2RAGE Sequence in Inflammatory Diseases of the Neuraxis (SCOUT-MS)
Observational
Fondation Ophtalmologique Adolphe de Rothschild (Voir sur ClinicalTrials)
juillet 2024
juillet 2026
17 octobre 2024
Since the last revision of the MRI guidelines in multiple sclerosis (MS, MAGNIMS) and the
McDonald criteria in 2017, all spinal cord lesions must be counted to increase the
sensitivity and specificity of the diagnosis of MS. Focal lesions of the spinal cord are
more frequently located in the cervical segments than in the lower segments of the spinal
cord and occupy the lateral and posterior columns, although the central grey matter may
not be spared. Cervical involvement is difficult to study because of the small size of
the lesions and the loss of signal in the cervical region. As a result, the detection of
cervical lesions on MRI is sub-optimal.
In this context, standardised acquisition protocols have been proposed.
For MRI of the spinal cord, at least two of the following sagittal sequences are
recommended: T2, STIR, double inversion recovery, T1 with gadolinium injection, and/or T2
axial acquisitions.
Recently, our team validated the superiority of 3D PSIR and 3D FGAPSIR sequences, which
offer better detection performance than T2 and STIR on 3 Tesla MRI.
Other studies have also shown the contribution of the MP2RAGE sequence to the detection
of spinal cord lesions in MS, compared with the set of sequences classically recommended.
The MP2RAGE sequence is a T1 sequence, which creates a composite image, limiting field
inhomogeneity bias while providing a quantitative T1 map. It has recently been optimised
for the spinal cord, and has been only minimally evaluated in the context of MS.
The aim of this study is to evaluate the effectiveness of the MP2RAGE sequence in
comparison with the set of conventional sequences recommended for the detection of spinal
cord lesions in MS patients.
Etablissements
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| HOPITAL FONDATION A. DE ROTHSCHILD | Yavchitz | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Patient aged over 18 years
- scheduled to undergo 1.5T or 3T MRI of the spinal cord as part of an initial
assessment or reassessment of inflammatory neuraxial disease.
- Express consent to participate in the study
- Member or beneficiary of a social security scheme
- Patient aged over 18 years
- scheduled to undergo 1.5T or 3T MRI of the spinal cord as part of an initial
assessment or reassessment of inflammatory neuraxial disease.
- Express consent to participate in the study
- Member or beneficiary of a social security scheme
- Patient benefiting from a legal protection measure
- Pregnant women
- Absolute or relative contraindication to 1.5T or 3T MRI